Company Email Format Management

Gedea Biotech AB

Biotechnology Research Se 15 employees

Employees: 15
Contacts: 3
Emails: 3
Phones: 1

gedeabiotech.com LinkedIn

Gedea Biotech AB Overview

Headquarters: Se
Website: gedeabiotech.com
Industry: Biotechnology Research
Employees: 15
Founded: 2015
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

antimicrobial resistance AMR FemTech Womens Health Bacterial Vaginosis

About Gedea Biotech AB

Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health and research into novel non-antimicrobial based treatments is timely.

Gedea Biotech AB Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Gedea Biotech AB Org Chart

Sample employees and titles

Name	Title	Location	Contact
Daniel Koppelkamm, Cfa	Venture Capital Investor and Activist	Zug, Switzerland	Email
Ton Berkien		Sweden	Email
Moti Vyas	Investor in Tanvi Foods (India) Ltd.	Edison, New Jersey, United States	Email Phone
Annette Säfholm	CEO at Gedea Biotech Ab		View